Clinical trials: Serious Bacterial Infection
INFECTIONS, Skin and Subcutaneous Tissue Bacterial Infections
Study of Accuracy of New Diagnostic Technology to Guide Rapid Antibiotic Treatment for Serious Infections
This research will test a new ultra-rapid technology (called ID/AST Accelerate system) that uses a digital microscope to identify bacteria based on their growth patterns.
- Conditions
- INFECTIONS, Skin and Subcutaneous Tissue Bacterial Infections, Healthcare-associated Infection, Infection Due to Resistant Bacteria
- Trial name
- NCT02796716
- Testing
- Testing on new technology called Accelerate ID/AST system
- Where
- United States
- Volunteers
- 2,102 people
- Sponsor
- Denver Health and Hospital Authority
Febrile Illness Acute, Meningitis, Bacterial
Febrile Infants Swedish Study
Approximately one million febrile infants aged ≤60 days present annually to pediatric emergency departments (PEDs) in Europe and the United States.
- Conditions
- Febrile Illness Acute, Meningitis, Bacterial, Urinary Tract Infection (Diagnosis), Invasive Bacterial Infection
- Trial name
- FISS (NCT07134751)
- Where
- 11 sites in Sweden
- Volunteers
- 2,000 people
- Sponsor
- Region Skane
Bacteremia, Endocarditis
Retrospective Evaluation of Safety and Efficacy of Daptomycin Used in Patients With Serious Gram-positive Infections
Before Daptomycin (Cubicin ®) approved by the U.S. FDA in 2003, There were large-scale clinical trials conducted that included more than 1,000 subjects and than Daptomycin got complicated skin and soft tissue infections (CSSSI)…
- Conditions
- Bacteremia, Endocarditis, Serious Gram-positive Infections
- Trial name
- NCT01301638
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Far Eastern Memorial Hospital
Serious Fungal Infections
Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® IV
This is non-interventional study of voriconazole IV formulation in clinical use, which was mandated by the Korean government agency following the approval of Vfend in the Republic of Korea.
- Trial name
- NCT01073618
- Testing
- voriconazole IV
- Volunteers
- 692 people
- Sponsor
- Pfizer
Gram-Positive Bacterial Infections, Staphylococcus Infections
Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)
To evaluate the safety and efficacy of tigecycline in the treatment of selected serious infections caused by VRE. The primary efficacy endpoint will be the clinical response for all subjects.
- Conditions
- Gram-Positive Bacterial Infections, Staphylococcus Infections, Vancomycin Resistance, Methicillin Resistance
- Trial name
- NCT00079976
- Testing
- Tigecycline
- Volunteers
- 174 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Serious Fungal Infections
Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® Tablet In Korea
This is a non-interventional study of voriconazole tablet in Korea which is mandated by the Korean government agency.
- Trial name
- NCT01073631
- Testing
- voriconazole tablet
- Volunteers
- 543 people
- Sponsor
- Pfizer
Infective Endocarditis, Cardiac Device Infection
Oritavancin for Treatment of Serious Cardiac Infections
Cardiac infections, including infective endocarditis and cardiovascular implantable electronic device infections, are associated with substantial morbidity and mortality and are commonly caused by gram-positive bacteria.
- Conditions
- Infective Endocarditis, Cardiac Device Infection, Gram-positive Bacterial Infections
- Trial name
- OSCAR (NCT07550595)
- Testing
- Oritavancin
- Where
- 3 sites in Australia
- Volunteers
- 20 people
- Sponsor
- Kirby Institute
Serious Bacterial Infection
Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria
Phase 3 study to determine the efficacy, safety, and tolerability of aztreonam- avibactam (ATM- AVI) versus best available therapy (BAT) in the treatment of hospitalized adults with complicated intra-abdominal infections (cIAI)…
- Trial name
- NCT03580044
- Testing
- ATM-AVI, BAT
- Where
- 42 sites in United States, Argentina and 10 more
- Volunteers
- 15 people
- Sponsor
- Pfizer